Group 1 - The company Guangxi Wuzhou Zhongheng Group Co., Ltd. announced that its subsidiary Chongqing Laimei Pharmaceutical Co., Ltd. and its wholly-owned subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd. participated in the national centralized procurement for drugs whose agreements have expired, with some products expected to be selected for procurement [1][2] - The selected products are projected to generate a total sales revenue of 106.19 million yuan in 2024, accounting for 4.68% of the company's total revenue for that year. For the first three quarters of 2025, the expected sales revenue is 66.07 million yuan, representing 3.39% of the company's revenue for that period [1][2] Group 2 - The procurement is organized by a national alliance consisting of various provinces and regions, with Jiangsu, Henan, and Guangdong provinces leading the initiative. The procurement aims to ensure that medical institutions prioritize the selected products, which is expected to enhance sales and market expansion for the company [2]

Group 1 - The core viewpoint of the news is that the national centralized procurement of medicines is expected to stabilize production and sales expectations in the pharmaceutical industry, with a high selection rate of 93% for the involved drugs [1] - The procurement involves 316 commonly used drugs across 26 treatment areas, including anti-infection and anti-tumor [1] - The procurement process is led by the National Healthcare Security Administration and will follow a unified national rule, with the procurement period extending until the end of 2028 [1] Group 2 - The stock price of Medisi has shown significant volatility in the recent trading days, with a peak increase of 7.20% on February 6, closing at 70.00 yuan [2] - On February 9, the stock price dropped by 4.29% to 67.00 yuan, influenced by market sentiment, followed by a slight increase of 0.28% on February 12, closing at 67.19 yuan [2] - The trading range for the stock during this period reached 21.97%, indicating active trading, with fluctuations in financing balance observed [2]

Core Viewpoint - Meinuo Pharma's wholly-owned subsidiary, Meinuo TianKang, is participating in the national organized procurement for drugs, with 10 products, including Perindopril tert-butylamine tablets, expected to be selected for procurement [1] Group 1 - The total sales revenue of the 10 products is projected to be 71.75 million yuan, accounting for 6.4% of the company's revenue for the first three quarters of 2025 [1] - The number of selected products represents 40% of the total number of formulations in the company's formulation segment [1] - The results of the selection process are expected to be finalized by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1] Group 2 - There is uncertainty regarding the signing of the procurement agreement and the execution of sales [1]

Core Viewpoint - Chengdu Shengnuo Biotechnology Co., Ltd. announced its participation in the national organized procurement of pharmaceuticals, with several products expected to be selected for the new round of procurement, which is a significant step for the company in expanding its market presence and enhancing competitiveness in the peptide pharmaceutical market [1][2]. Group 1: Selected Products - The company’s subsidiary, Chengdu Shengnuo Pharmaceutical Co., Ltd., participated in the national organized procurement for the first to eighth batches, with products such as Acetate Octreotide Injection and Acetate Atosiban Injection expected to be selected [1]. - The selected products include Acetate Octreotide Injection (seventh batch), Acetate Atosiban Injection (eighth batch), Somatostatin Injection (eighth batch), Thymosin Alpha 1 Injection, and Eptifibatide Injection [1]. Group 2: Impact on the Company - The selected products are expected to enhance the company's sales revenue significantly in 2024 and the first nine months of 2025, with the procurement cycle running until the end of 2028 [2]. - The procurement will prioritize the use of selected drugs in medical institutions, ensuring the completion of the agreed procurement volume, which is expected to positively impact the company's operational development [2]. - The selection also reflects the stability and reliability of the company's drug quality, which is crucial for its competitive position in the peptide pharmaceutical market [2].

Core Insights - The new round of national centralized procurement for medicines has resulted in 4,163 products from 1,020 companies being shortlisted, covering 316 commonly used drugs across 26 therapeutic areas [1][2] - The procurement results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028 [1] - The procurement process has seen a high participation rate from qualified companies, with an overall selection rate of 93%, indicating a diverse market supply and rich clinical choices [1] Group 1 - The centralized procurement is the first nationwide continuation of chemical drug procurement organized by the state, led by the medical insurance bureaus of Jiangsu, Henan, and Guangdong provinces [1] - The procurement rules have been standardized and unified across provinces, significantly reducing bidding costs for companies [1] - The clinical demand matching rate for the reported brand names reached 88%, with a high retention rate of previously selected products at 98%, which helps avoid medication replacement [1] Group 2 - The qualification threshold for bidding has been raised, with stricter quality requirements, including the need for companies to have experience in producing similar types of drugs and no violations of production quality management standards in the past two years [2] - The procurement adopted a pricing inquiry method based on previous winning prices, allowing companies to accurately calculate cost-benefit ratios and rationally quote prices, leading to stable selection prices and industry expectations [2]